JP2024522116A5 - - Google Patents
Info
- Publication number
- JP2024522116A5 JP2024522116A5 JP2023573353A JP2023573353A JP2024522116A5 JP 2024522116 A5 JP2024522116 A5 JP 2024522116A5 JP 2023573353 A JP2023573353 A JP 2023573353A JP 2023573353 A JP2023573353 A JP 2023573353A JP 2024522116 A5 JP2024522116 A5 JP 2024522116A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer cells
- antibody construct
- antibody
- muc1
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194597P | 2021-05-28 | 2021-05-28 | |
| US63/194,597 | 2021-05-28 | ||
| PCT/US2022/031431 WO2022251695A2 (en) | 2021-05-28 | 2022-05-27 | Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522116A JP2024522116A (ja) | 2024-06-11 |
| JP2024522116A5 true JP2024522116A5 (enExample) | 2025-05-02 |
Family
ID=84230363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573353A Pending JP2024522116A (ja) | 2021-05-28 | 2022-05-27 | Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する多重特異性抗体構築物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240262930A1 (enExample) |
| EP (1) | EP4346890A4 (enExample) |
| JP (1) | JP2024522116A (enExample) |
| KR (1) | KR20240021828A (enExample) |
| CN (1) | CN117769432A (enExample) |
| AU (1) | AU2022283436A1 (enExample) |
| BR (1) | BR112023024724A2 (enExample) |
| CA (1) | CA3220049A1 (enExample) |
| IL (1) | IL308881A (enExample) |
| MX (1) | MX2023014109A (enExample) |
| WO (1) | WO2022251695A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4644413A1 (en) * | 2024-05-03 | 2025-11-05 | Genmab B.V. | Binding agents having altered fc-mediated effector functions |
| WO2026024841A1 (en) * | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| EP2604279A1 (en) * | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| JP2012530721A (ja) * | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
| US20130189268A1 (en) * | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| US20150038682A1 (en) * | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| US10617773B2 (en) * | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
| WO2018178047A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
| EP3655439A1 (en) * | 2017-07-20 | 2020-05-27 | Aptevo Research and Development LLC | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| JP2021502100A (ja) * | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| SG11202008474QA (en) * | 2018-03-27 | 2020-10-29 | Systimmune Inc | Guidance and navigation control proteins and method of making and using thereof |
| US20210115152A1 (en) * | 2018-05-16 | 2021-04-22 | Arbele Limited | Composition of bispecific antibodies and method of use thereof |
| JP7495409B2 (ja) * | 2018-09-11 | 2024-06-04 | ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ | 改善された抗ｆｌｔ３抗原結合タンパク質 |
-
2022
- 2022-05-27 EP EP22812303.0A patent/EP4346890A4/en active Pending
- 2022-05-27 KR KR1020237043964A patent/KR20240021828A/ko active Pending
- 2022-05-27 AU AU2022283436A patent/AU2022283436A1/en active Pending
- 2022-05-27 JP JP2023573353A patent/JP2024522116A/ja active Pending
- 2022-05-27 MX MX2023014109A patent/MX2023014109A/es unknown
- 2022-05-27 WO PCT/US2022/031431 patent/WO2022251695A2/en not_active Ceased
- 2022-05-27 BR BR112023024724A patent/BR112023024724A2/pt unknown
- 2022-05-27 IL IL308881A patent/IL308881A/en unknown
- 2022-05-27 CA CA3220049A patent/CA3220049A1/en active Pending
- 2022-05-27 US US18/561,413 patent/US20240262930A1/en active Pending
- 2022-05-27 CN CN202280045669.5A patent/CN117769432A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515318A5 (enExample) | ||
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| Todorovska et al. | Design and application of diabodies, triabodies and tetrabodies for cancer targeting | |
| JP2021098733A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2021511811A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JP2017503480A5 (enExample) | ||
| RU2016125551A (ru) | Биспецифические антигенсвязывающие конструкции против her2 | |
| JP2010535713A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2023539501A5 (enExample) | ||
| JP2023516004A5 (enExample) | ||
| JP2022517920A5 (enExample) | ||
| CN103025760A (zh) | 人源化egfr抗体 | |
| JP2024522116A5 (enExample) | ||
| JP2021523140A5 (enExample) | ||
| JP2025038088A5 (enExample) | ||
| JP2022519120A5 (enExample) | ||
| JP2024508808A5 (enExample) | ||
| JP2025507817A5 (enExample) | ||
| CN111655733A (zh) | 共价多特异性抗体 | |
| JP2019505545A5 (enExample) |